US patent granted

RNS Number : 4820L

e-Therapeutics plc

12 January 2009

 



Press Release

12 January 2009

e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Patents granted for discovery technology in the USA

Further to the announcement on 11 November 2008, e-Therapeutics plc (AIM: ETX), the drug discovery and development company, is pleased to announce that it has now been granted patent protection for its in silico drug discovery technology in the USA. 

As previously announced, the Company's proprietary in silico technology has been shown to predict the effects of a drug compound's interactions with proteins both in cells related to a particular disease and in normal cells. This optimises the drug discovery process by identifying drugs that interact with specific proteins, to produce the desired therapeutic response with minimal side effects.

Patent protection for this technology has already been granted in Europe, the UK and India.  

Professor Malcolm Young, CEO of e-Therapeutics, said: 'The recent approvals of the patents for our discovery processes are a key milestone for the Company. Our successes in the clinic are showing the power of these new processes to discover safe and efficacious drugs in areas of medicine in which older approaches have often not succeeded and the patent approvals ensure this technology is protected.'

For further information:
e-Therapeutics plc	www.etherapeutics.co.uk
Malcolm Young [e-mail]	[phone]
Nominated Advisor: WH Ireland
Katy Mitchell [e-mail]	[phone]
Media enquiries:
Abchurch	www.abchurch-group.com
Heather Salmond/Stephanie Cuthbert/Simone Alves  [e-mail]	[phone]

Notes to Editors

e-Therapeutics plc is a drug discovery and development company. It has developed proprietary computational systems to swiftly and accurately analyse and predict how medicines interact with cells in the body. This optimises the probability of identifying drug candidates with desirable efficacy and low toxicity. The Company applies its novel, systematic approach to three areas of activity: 

	discovery of new drugs;
	discovering novel uses for existing drugs; and
	analysis of the interactions between different drugs.

Amongst e-Therapeutics' pipeline of compounds in development are novel antibiotics that kill the 'superbug' MRSA, and a novel cancer chemotherapy that kills malignant cells at safe doses in a very short time. Other candidate therapies in development are targeted at atherosclerosis, asthma and depression. The Company is currently in negotiation with a number of pharmaceutical companies, and is progressing the preclinical and clinical development of these products. 

- ends -

 

END

 

 

MSCXLLFFKFBLBBF